世界のバイオシミラー&バイオ後続品市場2023年~2033年

【英語タイトル】Biosimilars and Follow-On Biologics Market Report 2023-2033

visiongainが出版した調査資料(VGA22DV007)・商品コード:VGA22DV007
・発行会社(調査会社):visiongain
・発行日:2022年12月1日
・ページ数:337
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用、1年間、印刷不可)GBP3,950 ⇒換算¥711,000見積依頼/購入/質問フォーム
Enterprise(法人閲覧用、1年間、印刷可)GBP6,950 ⇒換算¥1,251,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Visiongain社の本調査レポートでは、世界のバイオシミラー&バイオ後続品市場規模が2033年までに年平均成長率31.14%で拡大すると予想しています。本レポートは、バイオシミラー&バイオ後続品の世界市場を調査対象とし、レポート概要、エグゼクティブサマリー、市場概要、製造別(自社、CMO(医薬品製造受託機関))分析、種類別(モノクローナル抗体、融合タンパク質、インスリン、エリスロポエチン、その他)分析、用途別(血液疾患、腫瘍疾患、慢性自己免疫疾患、成長ホルモン欠乏症、その他)分析、技術別(rDNA技術、mAb技術、バイオ分析技術)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ、アメリカ、カナダ、ドイツ、イギリス、フランス、イタリア、中国、日本、中国、インド、ブラジル、メキシコ、中東、南アフリカ、その他地域)分析、企業情報、提言などの項目を掲載しております。また本レポートには、3SBio, Inc.、AMEGA Biotech、Amgen Inc.、Apotex, Inc.、BIOCAD、Biocon Limited、Biogen, Inc.、Celltrion Healthcare Co.,Ltd.、Coherus BioSciences、Dr. Reddy’s Laboratories Ltd.などの企業情報が含まれています。
・レポート概要
・エグゼクティブサマリー
・市場概要

・世界のバイオシミラー&バイオ後続品市場規模:製造別
- 自社バイオシミラー&バイオ後続品の市場規模
- CMO(医薬品製造受託機関)バイオシミラー&バイオ後続品の市場規模

・世界のバイオシミラー&バイオ後続品市場規模:種類別
- モノクローナル抗体における市場規模
- 融合タンパク質における市場規模
- インスリンにおける市場規模
- エリスロポエチンにおける市場規模
- その他における市場規模

・世界のバイオシミラー&バイオ後続品市場規模:用途別
- 血液疾患における市場規模
- 腫瘍疾患における市場規模
- 慢性自己免疫疾患における市場規模
- 成長ホルモン欠乏症における市場規模
- その他における市場規模

・世界のバイオシミラー&バイオ後続品市場規模:技術別
- rDNA技術の市場規模
- mAb技術の市場規模
- バイオ分析技術の市場規模

・世界のバイオシミラー&バイオ後続品市場規模:地域別
- 北米のバイオシミラー&バイオ後続品市場規模
アメリカのバイオシミラー&バイオ後続品市場規模
カナダのバイオシミラー&バイオ後続品市場規模

- ヨーロッパのバイオシミラー&バイオ後続品市場規模
ドイツのバイオシミラー&バイオ後続品市場規模
イギリスのバイオシミラー&バイオ後続品市場規模
フランスのバイオシミラー&バイオ後続品市場規模
イタリアのバイオシミラー&バイオ後続品市場規模
その他地域のバイオシミラー&バイオ後続品市場規模

- アジア太平洋のバイオシミラー&バイオ後続品市場規模
日本のバイオシミラー&バイオ後続品市場規模
中国のバイオシミラー&バイオ後続品市場規模
インドのバイオシミラー&バイオ後続品市場規模
その他のバイオシミラー&バイオ後続品市場規模

- 中南米のバイオシミラー&バイオ後続品市場規模
ブラジルのバイオシミラー&バイオ後続品市場規模
メキシコのバイオシミラー&バイオ後続品市場規模
その他地域のバイオシミラー&バイオ後続品市場規模

- 中東・アフリカのバイオシミラー&バイオ後続品市場規模
中東のバイオシミラー&バイオ後続品市場規模
南アフリカのバイオシミラー&バイオ後続品市場規模
その他地域のバイオシミラー&バイオ後続品市場規模

・企業情報
・提言

The Biosimilars and Follow-On Biologics Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Regulatory Hurdles Slowing Down Access to Biosimilars
Even in mature areas where regulations for standard generics have been in place for some time, there are still certain challenges, particularly with regard to sophisticated generics. Product categories like respiratory and some long-acting injectables, for instance, still require a large amount of evidence production, which drives up costs and restricts the availability of generics in these markets. This is frequently accompanied by intellectual property (IP) disputes and legal actions, wherein originators are granted prolonged protection periods beyond the initial time intended for the submitted innovation, delaying Generics access.

In a similar vein, clinical trial expenses continue to be exorbitant despite the fact that the regulatory pathways for biosimilars have been well delineated. Even if it is predicted that improvements in regulatory science and characterisation abilities would lessen the necessity for such restrictions, this places researchers and producers at a high degree of risk.

Some emerging nations are still having trouble establishing the proper regulatory environment to facilitate quicker product development. While these variables have an impact on the development of generics and biosimilars, they have a stronger influence when players attempt to build a more inventive pipeline. It will be important to further simplify regulatory requirements to speed up market access while ensuring adequate quality and efficacy.

Emerging Economies Continues to Pose Challenges for Building Presence for Generics and Biosimilars Companies
While emerging nations provide a substantial development potential and an essential playing field for greater access to medicines, they also present major structural and competitive market challenges for generics and biosimilars enterprises. While fierce local competition makes it challenging for players to establish a presence in these markets, additional factors like unstable economic conditions, price controls, the push for local manufacturing in some markets, and shifting regulatory requirements across geographies are all affecting players’ ability to successfully focus on these markets. It may also be less enticing for international firms to join in and assist the development of these markets due to currency repercussions in certain of the countries. Past partnerships and acquisitions have had varying degrees of success, which has limited overall growth performance for players in these fields.

In these conditions, local players who are familiar with the dynamics of their own marketplaces may have an even greater potential to grow developing economies. International players will need to concentrate on careful selection of target nations (e.g., markets with legislative requirements that are comparable to other markets, such as the US and EU) and implement a tailored portfolio approach to avoid costly expansion initiatives with little immediate return.

What Questions Should You Ask before Buying a Market Research Report?
• How is the biosimilars and follow-on biologics market evolving?
• What is driving and restraining the biosimilars and follow-on biologics market?
• How will each biosimilars and follow-on biologics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each biosimilars and follow-on biologics submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading biosimilars and follow-on biologics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the biosimilars and follow-on biologics projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
biosimilars and follow-on biologics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the biosimilars and follow-on biologics market?
• Where is the biosimilars and follow-on biologics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the biosimilars and follow-on biologics market today, and over the next 10 years:
• Our 337-page report provides 127 tables and 154 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the biosimilars and follow-on biologics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Type of Manufacturing
• In-House
• CMOs

Type
• Monoclonal Antibodies
• Fusion Proteins
• Insulin
• Erythropoietin
• Granulocyte-Colony Stimulating Factor
• Interferon
• Growth Hormones
• Fertility Hormones
• Others

Application
• Blood Disorders
• Oncology Diseases
• Chronic & Autoimmune Diseases
• Growth Hormone Deficiencies
• Others

Technology
• RDNA Technology
• MAbs Technology
• Bioassay Technology

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific
• Japan
• China
• India
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Biosimilars and Follow-on Biologics Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• 3SBio, Inc.
• AMEGA Biotech
• Amgen Inc.
• Apotex, Inc.
• BIOCAD
• Biocon Limited
• Biogen, Inc.
• Celltrion Healthcare Co., Ltd.
• Coherus BioSciences
• Dr. Reddy’s Laboratories Ltd.
• Eli Lilly and Company
• Gedeon Richter PLC
• Intas Pharmaceutical Ltd.
• Mabxience SA
• Viatris Inc. (Mylan NV)
• Novartis AG
• Pfizer Inc.
• Samsung Bioepis Co. Ltd.
• Stada Arzneimittel AG
• Teva Pharmaceutical

Overall world revenue for Biosimilars and Follow-on Biologics Market, 2023 to 2033 in terms of value the market will surpass US$19,668 million in 2022, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biosimilars and Follow-on Biologics Market, 2023 to 2033 report help you?
In summary, our 330+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Biosimilars and Follow-on Biologics Market, 2023 to 2033 Market, with forecasts for Type of Manufacturing, Type, Application, Technology each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 18 key national markets – See forecasts for the Biosimilars and Follow-on Biologics Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 20 of the major companies involved in the Biosimilars and Follow-on Biologics Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Biosimilars and Follow-on Biologics Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

❖ レポートの目次 ❖

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Biosimilars and Follow-on Biologics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Incentivizing Providers to Adopt Biosimilars
3.2.1.2 Developed Regions Driving the Worldwide Biosimilars and Follow-on Biologics Market Growth
3.2.1.3 Biologics Patent Expiry Set to Open Fresh Revenue Pockets for Biosimilars Companies Over the Next Decade
3.2.1.4 Pricing Advantage of Biosimilars Comparison to Biologics Anticipated to Fuel Market Growth
3.2.2 Market Restraining Factors
3.2.2.1 High Cost Involvement, Uncertainty and Complexities in Manufacturing
3.2.2.2 Resistance from Biologics Manufacturers to Restrain Market Growth
3.2.2.3 Reluctance of Healthcare Providers to Switch to Biosimilars
3.2.3 Market Opportunities
3.2.3.1 Companies Can Use Information of Original Innovator thus Shorten Development & Approval Processes
3.2.3.2 Diversity in Approach Among the Authorities
3.3 Trends
3.3.1 Regulatory Hurdles Slowing Down Access to Biosimilars
3.3.2 Vulnerability of Global Pharmaceutical Manufacturing Amid COVID-19
3.3.3 Emerging Economies Continues to Pose Challenges for Building Presence for Generics and Biosimilars Companies
3.3.4 Digital Transformations as a Key Enabler to Strengthen Research in Biosimilars Industry
3.4 COVID-19 Impact Analysis
3.5 Porter’s Five Forces Analysis
3.5.1 Supplier Power
3.5.2 Buyer Power
3.5.3 Competitive Rivalry
3.5.4 Threat from Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis
3.6.1 Political Factors Impacting Biosimilars and Follow-on Biologics Market
3.6.2 Economic Factors Impacting Biosimilars and Follow-on Biologics Market
3.6.3 Social Factors Impacting Biosimilars and Follow-on Biologics Market
3.6.4 Technological Factors Impacting Biosimilars and Follow-on Biologics Market

4 Biosimilars and Follow-on Biologics Market Analysis by Type of Manufacturing
4.1 Key Findings
4.2 Type of Manufacturing Segment: Market Attractiveness Index
4.3 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Type of Manufacturing
4.4 In-House
4.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 CMOs
4.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
4.5.2 Market Share by Region, 2023 & 2033 (%)

5 Biosimilars and Follow-on Biologics Market Analysis by Type
5.1 Key Findings
5.2 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Type
5.3 Monoclonal Antibodies
5.3.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.3.2 Market Share by Region, 2023 & 2033 (%)
5.4 Fusion Proteins
5.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Insulin
5.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Erythropoietin
5.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Granulocyte-Colony Stimulating Factor
5.7.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.7.2 Market Share by Region, 2023 & 2033 (%)
5.8 Interferon
5.8.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.8.2 Market Share by Region, 2023 & 2033 (%)
5.9 Growth Hormones
5.9.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.9.2 Market Share by Region, 2023 & 2033 (%)
5.10 Fertility Hormones
5.10.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.10.2 Market Share by Region, 2023 & 2033 (%)
5.11 Others
5.11.1 Market Forecast by Region, 2023-2033 (US$ Mn)
5.11.2 Market Share by Region, 2023 & 2033 (%)

6 Biosimilars and Follow-on Biologics Market Analysis by Application
6.1 Key Findings
6.2 Application Segment: Market Attractiveness Index
6.3 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Application
6.4 Blood Disorders
6.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Oncology Diseases
6.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Chronic & Autoimmune Diseases
6.6.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.6.2 Market Share by Region, 2023 & 2033 (%)
6.7 Growth Hormone Deficiencies
6.7.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.7.2 Market Share by Region, 2023 & 2033 (%)
6.8 Others
6.8.1 Market Forecast by Region, 2023-2033 (US$ Mn)
6.8.2 Market Share by Region, 2023 & 2033 (%)

7 Biosimilars and Follow-on Biologics Market Analysis by Technology
7.1 Key Findings
7.2 Technology Segment: Market Attractiveness Index
7.3 Biosimilars and Follow-on Biologics Market Size Estimation and Forecast by Technology
7.4 rDNA Technology
7.4.1 Market Forecast by Region, 2023-2033 (US$ Mn)
7.4.2 Market Share by Region, 2023 & 2033 (%)
7.5 mAbs Technology
7.5.1 Market Forecast by Region, 2023-2033 (US$ Mn)
7.5.2 Market Share by Region, 2023 & 2033 (%)
7.6 Bioassay Technology
7.6.1.1 Chromatography
7.6.1.2 Mass Spectrometry
7.6.1.3 NMR (Nuclear Magnetic Resonance)
7.6.1.4 Electrophoresis
7.6.2 Market Forecast by Region, 2023-2033 (US$ Mn)
7.6.3 Market Share by Region, 2023 & 2033 (%)

8 Biosimilars and Follow-on Biologics Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Biosimilars and Follow-on Biologics Market Analysis
9.1 Key Findings
9.2 North America Biosimilars and Follow-on Biologics Market Attractiveness Index
9.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
9.5 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
9.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
9.7 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
9.8 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
9.9 U.S.
9.9.1 United States is Just Beginning to Catch Up European Biosimilars Market
9.9.2 Rising Biosimilar Uptake to Fuel U.S. Biosimilars Market Growth
9.9.3 Advancements in Biosimilars Development and Approvals Across the United States to Fuel Market Growth
9.10 Canada
9.10.1 Biosimilar Authorization Activity Across Canadian Region
9.10.2 Initiatives by Health Canada to Boost Canadian Biosimilars and Follow-on Biologics Market Over the Next Decade
9.10.3 Availability of Biosimilars in Oncology Treatment Landscape Driving Regional Growth
9.10.4 Canada Biosimilars and Follow-on Biologics Market Outlook

10 Europe Biosimilars and Follow-on Biologics Market Analysis
10.1 Key Findings
10.2 Growing Prevalence of Lifestyle Diseases Anticipated to Fuel European Biosimilars Market Growth
10.3 Continued Benefits of Biosimilars to Offer Lucrative Growth Prospects in Long Term
10.4 Europe Biosimilars and Follow-on Biologics Market Attractiveness Index
10.5 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
10.6 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
10.7 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
10.8 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
10.9 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
10.10 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
10.11 Germany
10.11.1 Biosimilars Have Been Accepted as an Important Component of Proper Medication Usage in Germany
10.11.2 Germany Intends to Switch to Biologics Pharmacies by August 2022 thus Jeopardising the Long-Term Viability of Biosimilars
10.11.3 Germany Biosimilars and Follow-on Biologics Market Outlook
10.12 UK
10.12.1 NHS Encouraging the Growth of Biosimilar Manufacturing in United Kingdom
10.12.2 Despite Price Reduction, Biosimilar Medications are not Widely Used in Retail Settings
10.12.3 UK Biosimilars and Follow-on Biologics Market Outlook
10.13 France
10.14 Italy
10.14.1 Italian Government Policies Anticipated to Fuel Development of Biosimilars Market Across the Region
10.14.2 Biosimilars to Help Reduce Price of Pharmaceuticals Across the Italian Region
10.15 Spain
10.15.1 Budget Impact Analysis of Biosimilar Products in Spain
10.16 Rest of Europe

11 Asia Pacific Biosimilars and Follow-on Biologics Market Analysis
11.1 Key Findings
11.2 Low Clinical Development Costs Coupled with Regulatory Framework Ease to Fuel Regional Growth
11.3 Indian Pharmaceutical Companies Have an Enormous Scope in the Biosimilars Market
11.4 Asia Pacific Biosimilars and Follow-on Biologics Market Attractiveness Index
11.5 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
11.6 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
11.7 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
11.8 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
11.9 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
11.10 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
11.11 Japan
11.11.1 Biosimilars to Bolster Japanese Healthcare System Growth Over the Next Decade
11.11.2 Japan still has a slow growth in this sector compared to US and EU
11.11.3 Introduction of Biosimilars to Boost Regional Growth
11.11.4 Ageing Japanese Population Demanding the Development of Biosimilars Over the Forecast Period
11.12 China
11.12.1 Significant Surge in Biosimilar Approvals to Drive Market Growth
11.12.2 Technological Advancements to Fuel Chinese Biosimilars Market Growth Over the Forecast Period
11.12.3 Expansion by Major Firms to Boost Chinese Biosimilars Market Growth
11.12.4 Overcrowding of Chinese Market Has Led to the Withdrawal of International Players
11.13 India
11.13.1 India Set to Become Sixth Largest Pharmaceutical Market By End of 2030
11.13.2 Renowned Pharmaceutical Companies Establishing Partnerships with Indian Pharma Companies
11.13.3 India Biosimilars and Follow-on Biologics Market Outlook
11.14 Rest of Asia Pacific

12 Latin America Biosimilars and Follow-on Biologics Market Analysis
12.1 Key Findings
12.2 Latin America Biosimilars and Follow-on Biologics Market Attractiveness Index
12.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
12.5 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
12.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
12.7 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
12.8 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
12.9 Brazil
12.9.1 Brazilian Biosimilars Regulations
12.10 Mexico
12.11 Rest of Latin America

13 MEA Biosimilars and Follow-on Biologics Market Analysis
13.1 Key Findings
13.2 MEA Biosimilars and Follow-on Biologics Market Attractiveness Index
13.3 Market Size by Country, 2022, 2027 & 2032 (US$ Mn)
13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ Mn)
13.5 Market Size Estimation and Forecast by Type of Manufacturing, 2023-2033 (US$ Mn)
13.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ Mn)
13.7 Market Size Estimation and Forecast by Application, 2023-2033 (US$ Mn)
13.8 Market Size Estimation and Forecast by Technology, 2023-2033 (US$ Mn)
13.9 GCC
13.9.1 GCC Gearing Up to Take Big Jump on Biosimilars
13.9.2 Collaborations Among Pharmaceutical Firms Across GCC to Offer Lucrative Growth Prospects for Market Players Over the Forecast Period
13.10 South Africa
13.10.1 South African Evolving Demographic and Epidemiological Profile to Offer Lucrative Growth Prospects
13.10.2 Presence of Major Pharmaceutical Firms to Intensify Competition
13.11 Rest of MEA

14 Company Profiles
14.1 3SBio, Inc.
14.1.1 Company Snapshot
14.1.2 Company Overview
14.1.3 Product Benchmarking
14.1.4 Strategic Outlook
14.2 AMEGA Biotech
14.2.1 Company Snapshot
14.2.2 Company Overview
14.2.3 Product Benchmarking
14.3 Amgen Inc.
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2015-2021
14.3.3.2 R&D Expenses, 2015-2021
14.3.3.3 Gross Profit, 2015-2021
14.3.4 Product Benchmarking
14.3.5 Strategic Outlook
14.4 Apotex, Inc.
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Product Benchmarking
14.5 BIOCAD
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Product Benchmarking
14.5.4 Strategic Outlook
14.6 Biocon Limited
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2017-2021
14.6.3.2 R&D Expenses, 2017-2021
14.6.3.3 Biosimilars Sales, 2017-2021
14.6.3.4 Business Segment Market Share, 2021
14.6.3.5 Geographic Market Share, 2021
14.6.4 Product Benchmarking
14.6.5 Strategic Outlook
14.7 Biogen, Inc.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Product Benchmarking
14.8 Celltrion Healthcare Co.,Ltd.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Product Benchmarking
14.8.4 Strategic Outlook
14.9 Coherus BioSciences
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Product Benchmarking
14.9.4 Strategic Outlook
14.10 Dr. Reddy’s Laboratories Ltd.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Product Benchmarking
14.11 Eli Lilly and Company
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Net Revenue, 2015-2021
14.11.3.2 R&D Expenses, 2015-2021
14.11.3.3 Gross Profit, 2015-2021
14.11.3.4 Geographic Revenue, 2018-2021
14.11.4 Product Benchmarking
14.11.5 Strategic Outlook
14.12 Gedeon Richter PLC
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Product Benchmarking
14.12.4 Strategic Outlook
14.13 Intas Pharmaceutical Ltd.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Product Benchmarking
14.14 Mabxience SA
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Product Benchmarking
14.14.4 Strategic Outlook
14.15 Viatris Inc. (Mylan NV)
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2015-2021
14.15.3.2 R&D Expenses, 2015-2021
14.15.3.3 Gross Profit, 2015-2021
14.15.4 Product Benchmarking
14.15.5 Strategic Outlook
14.16 Novartis AG
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Net Revenue, 2015-2021
14.16.3.2 R&D Expenses, 2015-2021
14.16.3.3 Gross Profit, 2015-2021
14.16.3.4 Net Sales by Business Segment, 2019-2021
14.16.3.5 Net sales to third parties by business franchise in the Sandoz Division, 2020
14.16.4 Product Benchmarking
14.16.5 Strategic Outlook
14.17 Pfizer Inc.
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.3.1 Net Revenue, 2015-2021
14.17.3.2 R&D Expenses, 2015-2021
14.17.3.3 Gross Profit, 2015-2021
14.17.3.4 Geographic Market Share, 2021
14.17.4 Product Benchmarking
14.17.5 Strategic Outlook
14.18 Samsung Bioepis Co. Ltd.
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Product Benchmarking
14.18.4 Strategic Outlook
14.19 Stada Arzneimittel AG
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2016-2020
14.19.3.2 Gross Profit, 2016-2020
14.19.3.3 Net Sales by Segment, 2019-2020
14.19.4 Product Benchmarking
14.19.5 Strategic Outlook
14.20 Teva Pharmaceutical
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Financial Analysis
14.20.3.1 Net Revenue, 2015-2021
14.20.3.2 R&D Expenses, 2015-2021
14.20.3.3 Gross Profit, 2015-2021
14.20.4 Product Benchmarking

15 Conclusion and Recommendations
15.1 Concluding Remarks from
15.2 Recommendations for Market Players



★調査レポート[世界のバイオシミラー&バイオ後続品市場2023年~2033年] (コード:VGA22DV007)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のバイオシミラー&バイオ後続品市場2023年~2033年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆